Official Title A Phase 2, double-blind, randomized, placebo-controlled study of nelotanserin versus placebo in patients with dementia with Lewy bodies (DLB) experiencing REM sleep behaviors (RBD)

Purpose

The purpose of this study is to evaluate the safety of the study drug called nelotanserin and to assess the effects of nelotanserin in those experiencing frequent REM sleep behavior disorders due to dementia with Lewy bodies. Nelotanserin (study drug) is an investigational product, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) or the government health agencies of any other countries.

Could this study be right for you?

• Age: 50-85
• Diagnosis: probable dementia with Lewy bodies or Parkinson's disease dementia
• AND diagnosis of REM sleep behavior disorder (RBD) with frequent RBD episodes
• Must have a study partner willing to serve as a collateral informant for study assessments
• MMSE Score: greater than or equal to 18 (Mini Mental State Examination score to be explained by the coordinator)

Age Range

50 and up

Official Title Perinatal Arterial Stroke: The I-ACQUIRE Study

Purpose

Children who suffered a stroke before or shortly after being born that was caused by blockage of blood flow in an artery, it often results in the child showing some weakness on one side of their body.

With this study, we want to find out if a type of therapy may help children who have weakness on one side of their body due to perinatal arterial ischemic stroke, learn how to better use their weaker arm.

All children will be in the study for about 13 - 15 months. Some children may be in the study for a longer period, depending on which treatment they receive during Phase 1 of the study. The I-ACQUIRE therapy involves fun learning and play, self-help activities, and manipulating interesting toys and objects.

Could this study be right for you?

• Your child must be between the ages of 8 and 36 months old when beginning this study
• Your child must have suffered a perinatal arterial ischemic stroke
• Upper limb weakness
• Parents must be able to participate at least 1x/week for therapy and 40-60 minutes/day at home

Official Title Shoulder Surgery Outcomes Registry

Purpose

This registry will collect outcomes data of patients undergoing shoulder surgery with Dr. Jonathan Barlow or Dr. Julie Bishop. The purpose of this registry is to provide a way to collect and store data for patients undergoing shoulder surgery to support the conduct of future research in an effort to improve patient outcomes.

Could this study be right for you?

• A patient undergoing surgery with Dr Jonathan Barlow or Dr Julie Bishop (will be asked to enroll once the clinical decision has been made to proceed with surgery)
• 18 to 89 years old
• Able to provide consent

Age Range

18 and up

Official Title AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke (ARCADIA)

Purpose

The purpose of this research study is to compare the effects (good and bad) of apixaban with the effects (good and bad) of aspirin in patients with unexplained strokes and atrial cardiopathy to see which is better at prevention of future strokes.

Could this study be right for you?

• You are at least 45 years old
• Clinical diagnosis of ischemic stroke* of unknown cause (ESUS or cryptogenic) in the last 120 days
• Underwent an echocardiogram as part of your stroke work up
• No history of atrial fibrillation (irregular heartbeat)
• No known allergy or intolerance to aspirin or apixaban

*An “ischemic” stroke is an injury to the brain caused by a blocked blood vessel supplying the brain.

Age Range

45 and up

Official Title The Ohio State Lupus, Vasculitis and Glomerulonephritis Registry

Purpose

The purpose of the OSU Lupus and Vasculitis Registry is to obtain clinical and laboratory information about lupus and vasculitis and glomerulonephritis.

Could this study be right for you?

Patients at the Ohio State University Rheumatology and Lupus Clinic with one of the following diagnoses who are ages 18 years of age and older:

• Systemic lupus erythematosus
• Discoid lupus
• Mixed connective tissue disorder
• Undifferentiated connective tissue disorder
• Wegener’s granulomatosus
• Microscopic polyangiitis
• Henoch-Schonlien Purpura
• Takayasu’s arteritis
• Giant cell/temporal arteritis
• Churg-Strauss vasculitis
• Other vasculitides
• IgA nephropathy
• Anti-GBM GN
• Membranous GN
• Minimal Change Disease
• Focal Segmental Glomerulosclerosis

Age Range

18 and up

Official Title A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis

Purpose

This research study is for those who have nonalcoholic steatohepatitis (NASH) (meaning your liver is swollen and damaged because of a buildup of fat in your liver) and some liver fibrosis (which is damaged and scarred liver tissue). Because of your condition, you may be eligible for a research study on an investigational drug for your condition. The Regenerate Study will assess the safety and effectiveness of the investigational medication obeticholic acid (OCA) compared to placebo in delaying specific medical conditions or health related issues that can occur in patients with nonalcoholic steatohepatitis (NASH) (meaning your liver is swollen and damaged because of a buildup of fat in your liver) and some liver fibrosis (which is damaged and scarred liver tissue).

Could this study be right for you?

• Age 18 or older
• Diagnosed with Stage 2 or 3 NASH (nonalcoholic steatohepatitis--meaning your liver is swollen and damaged because of a buildup of fat in your liver) and some liver fibrosis (which is damaged and scarred liver tissue).

If you are eligible and decide to take part in this research study, you will need to complete 1 or 2 screening visits to see if you are eligible to participate in the study. Once the study doctor determines you can participate in the study, you will be asked to come back to the clinic 8 times (for the Month 0 [Day 1] Visit, the Month 1 Visit, the Month 3 Visit, and then every 3 months) for the first 18 months you are in the study and then 2 times per year (every 6 months) for each additional year you are in the study.

Age Range

18 and up

Official Title Registry of Deep Brain Stimulation with the VERCISE™ System: Vercise™ DBS Registry

Purpose

The purpose of this study is to record the personal experiences of those who have had Deep Brain Stimulation (DBS) using the Vercise™ System, for the treatment of Parkinson's Disease.

Could this study be right for you?

You may be eligible if you are:

• At least 18 years of age
• Planning to receive the currently available Vercise™ System and/or any new commercially approved parts such as leads, extension, Adaptor, CP, etc. that works with the Vercise System

Age Range

18 and up